Cargando…

MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer

Background: Cervical cancer is the fourth most common cancer among females worldwide. Identifying peptide patterns discriminating healthy individuals from those with diseases has gained interest in the early detection of cancers. Our study aimed to determine signature peptide patterns for cervical c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rungkamoltip, Phetploy, Roytrakul, Sittiruk, Navakanitworakul, Raphatphorn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452062/
https://www.ncbi.nlm.nih.gov/pubmed/37626823
http://dx.doi.org/10.3390/biomedicines11082327
_version_ 1785095573680947200
author Rungkamoltip, Phetploy
Roytrakul, Sittiruk
Navakanitworakul, Raphatphorn
author_facet Rungkamoltip, Phetploy
Roytrakul, Sittiruk
Navakanitworakul, Raphatphorn
author_sort Rungkamoltip, Phetploy
collection PubMed
description Background: Cervical cancer is the fourth most common cancer among females worldwide. Identifying peptide patterns discriminating healthy individuals from those with diseases has gained interest in the early detection of cancers. Our study aimed to determine signature peptide patterns for cervical cancer screening. Methods: Our study focused on the serum peptidome analysis of 83 healthy women and 139 patients with cervical cancer. All spectra derived from matrix-assisted laser desorption/ionization time-of-flight mass spectrometry were analyzed using FlexAnalysis 3.0 and ClinProTools 2.2 software. Results: In the mass range of 1000–10,000 Da, the total average spectra were represented as the signature pattern. Principal component analysis showed that all the groups were separately distributed. Furthermore, the peaks at m/z 1466.91, 1898.01, 3159.09, and 4299.40 significantly differed among the investigated groups (Wilcoxon/Kruskal–Wallis test and ANOVA, p < 0.001). Conclusions: Laboratory-based rapid mass spectrometry showed that serum peptidome patterns could serve as diagnostic tools for diagnosing cervical cancer; however, verification through larger cohorts and association with clinical data are required, and the use of externally validated samples, such as patients with other types of cancers, should be investigated to validate the specific peptide patterns.
format Online
Article
Text
id pubmed-10452062
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104520622023-08-26 MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer Rungkamoltip, Phetploy Roytrakul, Sittiruk Navakanitworakul, Raphatphorn Biomedicines Article Background: Cervical cancer is the fourth most common cancer among females worldwide. Identifying peptide patterns discriminating healthy individuals from those with diseases has gained interest in the early detection of cancers. Our study aimed to determine signature peptide patterns for cervical cancer screening. Methods: Our study focused on the serum peptidome analysis of 83 healthy women and 139 patients with cervical cancer. All spectra derived from matrix-assisted laser desorption/ionization time-of-flight mass spectrometry were analyzed using FlexAnalysis 3.0 and ClinProTools 2.2 software. Results: In the mass range of 1000–10,000 Da, the total average spectra were represented as the signature pattern. Principal component analysis showed that all the groups were separately distributed. Furthermore, the peaks at m/z 1466.91, 1898.01, 3159.09, and 4299.40 significantly differed among the investigated groups (Wilcoxon/Kruskal–Wallis test and ANOVA, p < 0.001). Conclusions: Laboratory-based rapid mass spectrometry showed that serum peptidome patterns could serve as diagnostic tools for diagnosing cervical cancer; however, verification through larger cohorts and association with clinical data are required, and the use of externally validated samples, such as patients with other types of cancers, should be investigated to validate the specific peptide patterns. MDPI 2023-08-21 /pmc/articles/PMC10452062/ /pubmed/37626823 http://dx.doi.org/10.3390/biomedicines11082327 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rungkamoltip, Phetploy
Roytrakul, Sittiruk
Navakanitworakul, Raphatphorn
MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer
title MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer
title_full MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer
title_fullStr MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer
title_full_unstemmed MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer
title_short MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer
title_sort maldi-tof ms analysis of serum peptidome patterns in cervical cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452062/
https://www.ncbi.nlm.nih.gov/pubmed/37626823
http://dx.doi.org/10.3390/biomedicines11082327
work_keys_str_mv AT rungkamoltipphetploy malditofmsanalysisofserumpeptidomepatternsincervicalcancer
AT roytrakulsittiruk malditofmsanalysisofserumpeptidomepatternsincervicalcancer
AT navakanitworakulraphatphorn malditofmsanalysisofserumpeptidomepatternsincervicalcancer